仟源医药: 薪酬与考核委员会关于公司2025年限制性股票激励计划激励对象首次授予名单（截止授予日）的核查意见

Core Viewpoint - The Compensation and Assessment Committee of Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has reviewed and approved the list of initial grant recipients for the 2025 restricted stock incentive plan, confirming that all recipients meet the necessary legal and regulatory conditions [1][2]. Group 1 - The committee's review was based on relevant laws and regulations, including the Company Law, Securities Law, and the Management Measures for Equity Incentives of Listed Companies [1]. - The committee identified that none of the recipients were deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months [1]. - The committee has agreed to grant a total of 7.95 million shares of restricted stock to 171 recipients, with the grant date set for August 8, 2025 [2].